Generally, thrombocytosis is a laboratory finding in 10–57% of patients with malignancy, as a variety of neoplastic cells can stimulate platelet activation [75, 76]; some studies have revealed that cancer cells secrete vascular endothelial growth factor (VEGF), which also stimulates megakaryocyte differentiation [77]. This evidence concerns the gene VEGFA and cancer.